Top

Strahlentherapie und Onkologie

Published in:

01-06-2012 | Case study

Relapsing high grade mucoepidermoid carcinoma

Long-lasting complete response following reirradiation and EGFR blockade

Authors: Dr. D. Milanovic, B. Jeremic, G. Kayser, H.C. Rischke, J. Pfeiffer, A. Henke

Published in: Strahlentherapie und Onkologie | Issue 6/2012

Abstract

Background and purpose

The treatment strategy for inoperable recurrent mucoepidermoid carcinoma (MEC) is not well established. Here, we present a case of a relapsed high grade MEC of the salivary glands of the hard palate that was successfully treated with a reirradiation (re-RT) and cetuximab, an antibody against epidermal growth factor receptor (EGFR).

Case report

Twelve years after resection and adjuvant radiotherapy for high grade MEC of the salivary glands, a patient presented with inoperable recurrent disease. She received another 59.4 Gy. In addition, 400 mg/m² cetuximab was administered in the first week, followed by six additional weekly courses at 250 mg/m².

Results

Treatment was well tolerated. The patient is doing well and continuous radiological complete response (CR) is documented for 25 months after completion of the combined treatment.

Conclusion

Combined re-RT and targeted inhibition of EGFR with cetuximab may be a valuable therapeutic strategy in patients with recurrent localized high grade MEC who are not candidates for radical surgery.

Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28PubMedCrossRef

Brohl A, Steadman K, Kallakury B, Deeken JF (2010) Efficacy of combining targeted therapies cetuximab and dasatinib for resistant salivary gland carcinomas in vitro. J Clin Oncol 28:15S (abstr 5557)

Burdak-Rothkamm S, Rübe CE, Nguyen TP et al (2005) Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa). Strahlenther Onkol 181:197–204PubMedCrossRef

Buerger H, Gebhardt F, Schmidt H et al (2000) Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 60:854–857PubMed

Dittmann K, Mayer C, Rodemann HP (2010) Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function. Strahlenther Onkol 186:1–6PubMedCrossRef

Erovic BM, Schopper C, Pammer J et al (2010) Multimodal treatment of patients with minor salivary gland cancer in the case of recurrent disease. Head Neck 32:1167–1172PubMedCrossRef

Gebhardt F, Bürger H, Brandt B (2000) Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations—a link between genetics and epigenetics. Histol Histopathol 15:929–936PubMed

Gibbons MD, Manne U, Carroll WR et al (2001) Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope 111:1373–1378PubMedCrossRef

Glisson BS, Blumenschein G, Francisco M et al (2005) Phase II trial of gefitinib in patients with incurable salivary gland cancer. J Clin Oncol 23:580S (abstr 5532)

10.

Goode RK, Auclair PL, Ellis GL (1998) Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer 82:1217–1224PubMedCrossRef

11.

Grisanti S, Amoroso V, Buglione M et al (2008) Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literature. J Med Case Reports 30:320CrossRef

12.

Guzzo M, Locati LD, Prott FJ et al (2010) Major and minor salivary gland tumors. Crit Rev Oncol Hematol 74:134–148PubMedCrossRef

13.

Hoebers F, Heemsbergen W, Moor S et al (2011) Reirradiation for head-and-neck cancer: delicate balance between effectiveness and toxicity. Int J Radiat Oncol Biol Phys 81:e111–118PubMedCrossRef

14.

Laurie SA, Licitra L (2006) Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24:2673–2678PubMedCrossRef

15.

Licitra L, Mesia R, Rivera F et al (2011) Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 22:1078–1087PubMedCrossRef

16.

Locati LD, Bossi P, Perrone F et al (2009) Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45:574–578PubMedCrossRef

17.

Lujan B, Hakim S, Moyano S et al (2010) Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer 103:510–516PubMedCrossRef

18.

Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedCrossRef

19.

Milas L, Fan Z, Andratschke NH, Ang KK (2004) Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 58:966–971PubMedCrossRef

20.

Monteiro LS, Bento MJ, Palmeira C et al (2009) Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours. J Oral Pathol Med 38:508–513PubMedCrossRef

21.

Nance MA, Seethala RR, Wang Y et al (2008) Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma. Cancer 113:2082–2089PubMedCrossRef

22.

Balermpas P, Hambek M, Seitz O et al (2009) Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck. Strahlenther Onkol 185:775–781PubMedCrossRef

23.

Platteaux N, Dirix P, Vanstraelen B et al (2011) Outcome after re-irradiation of head and neck cancer patients. Strahlenther Onkol 187:23–31PubMedCrossRef

24.

Seethala RR (2011) Histologic grading and prognostic biomarkers in salivary gland carcinomas. Adv Anat Pathol 18:29–45PubMedCrossRef

25.

Selzer E, Liederer S, Lemaire C et al (2011) Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab. Strahlenther Onkol 187:373–377PubMedCrossRef

26.

Sholl LM, John Iafrate A, Chou YP et al (2007) Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod Pathol 20:1028–1035PubMedCrossRef

27.

Tsuchihashi Z, Khambata-Ford S, Hanna N et al (2005) Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 353:208–209PubMedCrossRef

28.

Zwicker F, Roeder F, Thieke C et al (2011) IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther Onkol 187:32–38PubMedCrossRef

Title: Relapsing high grade mucoepidermoid carcinoma
Long-lasting complete response following reirradiation and EGFR blockade
Authors: Dr. D. Milanovic
B. Jeremic
G. Kayser
H.C. Rischke
J. Pfeiffer
A. Henke
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: Strahlentherapie und Onkologie / Issue 6/2012
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0096-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Relapsing high grade mucoepidermoid carcinoma

Long-lasting complete response following reirradiation and EGFR blockade

Abstract

Background and purpose

Case report

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and purpose

Case report

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2012

Metastatic spinal cord compression in non-small cell lung cancer patients

Mitteilungen

Nachteile für ältere Patientinnen mit Mammakarzinom durch Untertherapie

Radiotherapy in stage I–III follicular non-Hodgkin lymphoma

Patient satisfaction during radiation therapy

Strukturelle Veränderungen der weißen Hirnsubstanz durch Chemotherapie und ihre Korrelation mit kognitiven Beeinträchtigungen